Skip to main content
To reach our Akron campus on marathon morning, Sept. 29, please follow these driving directions.
Go to homepage

Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis

Description:

For complete study information, please visit clinicaltrials.gov

Interested in participating?
We are currently recruiting
Study Sponsor:

Vertex Pharmaceuticals Incorporated

Full IRB Study Title:
A Phase 2, Randomized, Double‑blind, Controlled Study to Evaluate the Safety of VX‑152 Combination Therapy in Adults With Cystic Fibrosis Protocol: VX16-152-102
IRB Study ID:
968803-8
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Gregory Omlor, MD, FAAP

Director, Lewis H Walker CF Center; Pediatric Pulmonologist
Lewis H. Walker, MD, Cystic Fibrosis CenterRobert T. Stone, MD, Respiratory CenterPediatric Sleep Center